Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Common drug shows promise in extending lifespan
USC Dornsife research shows mifepristone, used for early pregnancy termination, may extend lifespan by boosting mitophagy, similar to rapamycin, though combining both drugs slightly reduces lifespan. This suggests both drugs act through the same pathway, potentially paving the way for anti-aging treatments.
How Longevity Drugs for Dogs Could Lead to Healthier Human Lives
Scientists and investors seek a drug to slow aging, exploring metformin and rapamycin, but the breakthrough might not come from human research.
Could a drug used in organ transplants slow aging?
A drug used for kidney transplant recipients, rapamycin, may have anti-aging benefits for hair, skin, heart, and immune health, according to a systematic review in The Lancet. Studies suggest rapamycin and its derivatives positively impact immune, cardiovascular, and integumentary systems. Animal studies indicate lifespan extension by targeting the mTOR pathway. Rapamycin, an mTOR inhibitor, could regulate human aging, but more research is needed on its effects on respiratory, digestion, kidney, and reproductive functions.
The Potential Role of Cannabidiol in Cosmetic Dermatology: A Literature Review
CBD enhances cell viability, reduces ROS, lipid peroxidation, and LDH release in UV-exposed keratinocytes and melanocytes. It also upregulates NRF-2, HOMX1, and PPARγ, and downregulates NF-κB and MMP-9 in various cell types. CBD shows anti-inflammatory effects in TNF-α and poly-(I:C)-treated HaCaT cells, and reduces paw edema in carrageenan-induced inflammation in rats and mice. Clinical studies indicate CBD improves psoriasis, atopic dermatitis, and acne symptoms, enhances wound healing, and combats aging effects.
Palvella Therapeutics awarded up to $2.6 mn grant from US FDA OOPD to support phase 3
Palvella Therapeutics received a $2.6 million grant from the FDA to support its phase 3 SELVA trial of Qtorin rapamycin for treating microcystic lymphatic malformations, a rare, debilitating genetic disease. Qtorin rapamycin aims to locally treat the disease by targeting the PI3K/mTOR pathway while minimizing systemic exposure and adverse events.
Biodexa Provides Update on Progression Free and Overall
Biodexa updates on Phase 1 study of MTX110 in recurrent glioblastoma, showing favorable overall survival compared to published rates. Patients in Cohort A had OS of 12-13 months, with two still in follow-up.
Safer Epilepsy Treatment for Pregnant Women with Drug Combo
Rapamycin may counteract Sodium Valproate's harmful effects on fetal spinal cord development, allowing safer use during pregnancy for women with epilepsy, according to University of Queensland researchers.
FDA Approves Drug For Rare Niemann-Pick Disease Type C
FDA approves IntraBio's drug Aqneursa for Niemann-Pick disease type C, Amgen reports success for eczema and myasthenia gravis treatments, AI tool TxGNN identifies old drugs for rare diseases, and rapamycin is explored for anti-aging benefits.
Synex founder, once detained at the border with a 80-pound magnet, is building portable ...
Synex Medical, founded by Ben Nashman, aims to develop a portable MRI for non-invasive glucose testing, raising $21.8 million in Series A funding. The prototype, currently toaster-sized, uses MRI and magnetic resonance spectroscopy to track glucose and other molecules. Despite challenges, Nashman's vision is to create a device small enough for personal use, revolutionizing diabetes care and predictive medicine.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath